I. Core Principle and the Agatston Score
Coronary artery calcium scoring is a non-contrast, low-radiation (~1 mSv) ECG-gated CT. Macroscopic calcification in the epicardial coronaries is a pathognomonic marker of atherosclerosis. It measures plaque burden, not percent stenosis.
The Agatston method multiplies calcified lesion area by a density factor (1–4). It remains the universal quantitative language for guidelines and exams.
Always interpret absolute score together with age–sex–race percentile (MESA). A modest score in a young South Asian man can be ≥75th percentile and is therefore high risk.
II. What Changed in 2025–2026
The original 2018/2019 ACC/AHA frame (CAC as a Class IIa “tie-breaker” after the Pooled Cohort Equations) is no longer the complete story. The 2026 ACC/AHA dyslipidemia guideline, 2024 ESC chronic coronary syndrome guidance, and the 2025 AHA scientific statement on opportunistic CAC expanded both the indication and the therapeutic consequence of the score.
1. Risk calculator: PCE → PREVENT
US documents now use the PREVENT ASCVD equations. Older PCE scores overestimated 10-year risk by roughly 40–50% in contemporary cohorts.
Selective CAC is recommended when 10-year PREVENT risk is about 3% to <10% (borderline to intermediate) and the treatment decision remains uncertain after a clinician–patient discussion.
Recommendation class in 2026 US lipid guidance: Class I for selective use — still not universal screening.
2. CAC now maps to LDL-C intensity, not only “start vs defer statin”
This is the highest-yield 2026 change for practical exams and clinic notes.
3. Incidental CAC is now guideline-actionable
Coronary calcium seen on a non-gated chest CT (visual read or validated AI) should be used to start or intensify lipid-lowering therapy.
Presence of calcium on non-gated CT = high-specificity evidence of atherosclerosis.
Absence of calcium on non-gated CT ≠ Power of Zero. Slice thickness, motion and incomplete coverage make a “zero” unreliable. Only a dedicated ECG-gated scan can claim CAC = 0.
SCCT / STR: at least qualitative reporting of CAC on every noncardiac chest CT is Class I. Use CAC-DRS language (mild / moderate / severe + vessel number). Visual mild / moderate / severe ≈ Agatston 1–99 / 100–299 / ≥300.
CMS (US) created a dedicated outpatient code pathway in 2026 for algorithmic CAC/AVC quantification from chest CT — a signal that opportunistic reporting is moving from “nice to have” to operational standard.
4. CAC ≥1000 is a distinct very-high-risk phenotype
Event rates approach secondary prevention. The exam answer is high-intensity statin plus additional lipid-lowering therapy if LDL remains above target — not “repeat CAC in two years” and not a moderate-intensity statin alone.
5. ESC 2024 CCS alignment
CACS may be used to refine risk around treatment thresholds (IIa/IIb depending on statement).
Very high CAC, whether sought or incidental, is treated as very high cardiovascular risk.
In suspected CCS with low pretest likelihood (>5–15%), CACS can reclassify patients toward very-low (≤5%) likelihood and support deferral of further testing.
CCTA remains first-line anatomy testing for most symptomatic patients with low-to-moderate likelihood. Standalone CAC does not rule out obstructive CAD in typical angina.
6. Power of Zero — still valid, slightly more precise
A dedicated gated CAC of exactly 0 still indicates exceptionally low near-term (≈10-year) event rates, typically <1.5% in selected intermediate-risk adults, and supports statin deferral (Class IIa logic retained).
Do not use CAC = 0 to withhold therapy in: diabetes mellitus; active heavy smokers; massive family history of premature CAD; already very high calculated risk (≥20%); and, in contemporary practice, very high Lp(a). These groups frequently harbour unstable non-calcified plaque.
Research note (not yet exam replacement): AI “Agatston 2.0” and photon-counting CT can detect subtle calcium below the classic 130 HU threshold in a subset of “CAC 0” scans, with higher subsequent event and conversion rates. Until guidelines rewrite Agatston zero, the clinical Power of Zero still refers to a dedicated gated Agatston score of 0.
7. Statin paradox — unchanged and still Class III
Intravascular imaging (OCT/IVUS) shows that statins shrink or halt the necrotic lipid core while promoting macroscopic calcification (“calcific healing”). The CAC number therefore often rises after statin initiation. Serial CAC “to see if the statin is working” is contraindicated (Class III, Harm).
8. CAC-DRS reporting remains mandatory thinking
Report total score and number of vessels involved. A CAC of 100 confined to distal RCA is lower risk than a CAC of 100 spread across left main, LAD and LCx. Diffuse multivessel calcium upgrades concern even when the absolute score looks only “moderate.”
III. Clinical Uses That Still Matter
A. Primary prevention — the risk reclassifier
Clinical dilemma: calculators under- or over-estimate biological risk, especially in intermediate-risk and high-risk ethnicities (South Asian ancestry is an ACC/AHA risk enhancer).
Landmark evidence: MESA — CAC is among the strongest predictors of future ASCVD events, outperforming hs-CRP, family history alone, or lipid panels used in isolation.
Action: CAC ≥100 AU or ≥75th percentile → reclassify to higher risk and start statin. In 2026 language, also assign the matching LDL target.
B. Guiding aspirin in primary prevention
Routine aspirin in primary prevention has been downgraded (Class III / harm in many adults) after ASPREE and ARRIVE, because bleeding often outweighs ischemic benefit. MESA sub-analyses still support considering low-dose aspirin when CAC ≥100, where absolute MI reduction more often exceeds major GI bleed risk. CAC does not automatically mandate DAPT or “blood thinners.”
C. Symptomatic patients — a narrow, very-low-risk role
Coronary CTA is the Class I anatomic test for most stable chest-pain pathways.
Standalone CAC has a limited ER / triage role only in very-low pretest probability plus normal serial troponins.
In that sliver, CAC = 0 carries NPV ~99% for obstructive CAD and can support discharge without immediate stress testing.
Do not use CAC to “clear” typical angina, rising troponin, or intermediate-high likelihood disease.
D. Extra-cardiac and opportunistic clues
Breast arterial calcification on mammography correlates with coronary calcium and is an emerging trigger to discuss a formal gated CAC scan in women.
AI platforms can now estimate Agatston-equivalent scores, epicardial fat and even aortic-valve calcium from routine or contrast-enhanced chest CT. Presence still drives prevention; absence on non-gated imaging does not.
IV. Must-Know Clinical Algorithm (2026)
V. Indian / CSI Context (Premature CAD Epidemic)
South Asian cohorts develop aggressive CAD almost a decade earlier than many Western populations, driven by central adiposity, insulin resistance and high lipoprotein(a). Western calculators systematically under-call this risk. CAC is therefore the practical arbiter of biological versus chronological age.
Age threshold: Western documents usually start at 40–45 years. CSI-oriented teaching and Indian preventive practice often consider CAC from about age 35 in Indian men with strong premature family history or elevated Lp(a), because the first fatal MI may occur in the early 40s.
Lp(a) once in adult life plus selective CAC is the high-yield Indian pair.
REACH–Rural India (asymptomatic adults 35–65) found CAC in about 1 in 4 participants (higher in men), showing that subclinical calcified atherosclerosis is not an urban-only problem.
Some Indian government and private health-check programmes now offer low-cost CT calcium scoring as an alternative when treadmill testing is not feasible. Selection still matters: not for ACS, not in pregnancy, not as a substitute for CCTA in typical angina.
VI. Exam Traps
CAC = 0 ≠ no atherosclerosis. It means no detectable calcified plaque by Agatston rules.
CAC ≠ percent stenosis. A score of 900 is burden, not a 90% blockage. Someone with CAC 0 can still have a soft-plaque stenosis.
Do not serial-scan patients already on statins.
Non-gated “no calcium” is not the Power of Zero. Non-gated “yes calcium” is enough to intensify prevention.
CAC ≥1000 = very high risk, not “just start a moderate statin.”
Vessel distribution can outrank a modest total score.
Do not use standalone CAC to rule out obstructive CAD in typical or intermediate-high likelihood chest pain.
Aspirin is a CAC-modifier discussion at ≥100, not automatic dual antiplatelet therapy.
VII. Quick Viva Cards
VIII. Sources informing this update
2018/2019 ACC/AHA cholesterol and primary-prevention guidelines (historical Class IIa CAC frame); 2021 multisociety chest-pain guideline; 2024 ESC Guidelines on chronic coronary syndromes; 2025 AHA Scientific Statement on opportunistic CAC detection on noncardiac chest CT; SCCT CAC-DRS / STR reporting standards; 2026 ACC/AHA multisociety dyslipidemia guideline discussions of PREVENT, CAC-mapped LDL targets and incidental CAC; MESA; contemporary reviews on CAC ≥1000 and AI opportunistic scoring. Indian framing draws on CSI / LAI lipid consensus teaching and South Asian premature-CAD epidemiology.
meritmedscript.blogspot.com · Cardiology exam notes · September 2026
Comments
Post a Comment
Join the academic discussion. Share your clinical insights, questions, or perspectives below.